# US 2021/0277057 A1 · Advantageous mu-opiate receptor peptide compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277057 A1
- Document ID: US20210277057A1
- Status: Published application
- Kind: A1
- Application number: 17/328,045
- Filed: 2021-05-24
- Published: 2021-09-09
- Earliest claimed: 2009-09-15
- Assignees: Cytogel Pharma, LLC
- Applicants: Cytogel Pharma, LLC
- Inventors: Theodore E. MAIONE
- Web page: https://patentgrep.com/patent/US20210277057A1

## CPC

- C07K 5/126: {Tetrapeptides}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 5/1016: {and aromatic or cycloaliphatic}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their activity.

## Claims

### Claim 1

A safe and effective method for treating a condition in a human that is modulated by μ-opiate receptor activity, wherein said method comprises administering, to a human patient in need of such treatment, a peptide compound wherein the compound is the acetate salt of SEQ ID NO: 13.

### Claim 2 (depends on 1)

The method, according to claim 1, which is used to provide analgesia or to treat a condition selected from the group consisting of gastrointestinal disorders, inflammation, and drug dependence.

### Claim 3 (depends on 1)

The method, according to claim 1, wherein the compound is administered enterally.

### Claim 4 (depends on 1)

The method, according to claim 1, wherein the compound is administered parenterally.

### Claim 5 (depends on 1)

The method, according to claim 1, wherein the composition is formulated as a solution.

### Claim 6 (depends on 1)

The method, according to claim 1, comprising administering a unit dose of from 2 mg to 50 mg of the acetate salt of SEQ ID NO:13.

### Claim 7 (depends on 5)

The method, according to claim 5, comprising administering a unit dose of from 2 mg to 50 mg of the acetate salt of SEQ ID NO:13.